Found 1 matching record:
HXB2 Location | Gag(162-172) | Gag Epitope Map
View variants at this location |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Epitope |
KAFSPEVIPMF
|
Epitope Alignment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Variants |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Epitope Name | KF11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Species (MHC/HLA) | human(B*57:01) |
Showing all: 51 variant(s).
Variant ID. | 4656 |
---|---|
Epitope Seq. | {E}KAFSPEVIPMF |
Variant Seq. | {k}KAFSPEVIPMF |
Mutations | E/K |
Epitope Location | E-1K |
HXB2 Location | E161K |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, kKAFSPEVIPMF (-1 to the start of epitope KF11) had an increased replicative capacity but did not have an increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones vs. without CTLs. |
Variant ID. | 4657 |
---|---|
Epitope Seq. | {E}KAFSPEVIPMF |
Variant Seq. | {d}KAFSPEVIPMF |
Mutations | E/D |
Epitope Location | E-1D |
HXB2 Location | E161D |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, dKAFSPEVIPMF (-1 to the start of epitope KF11) had at least a 2-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones vs. without CTLs. |
Variant ID. | 4658 |
---|---|
Epitope Seq. | KAFSPEVIPMF{S} |
Variant Seq. | KAFSPEVIPMF{a} |
Mutations | S/A |
Epitope Location | S+1A |
HXB2 Location | S173A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFSPEVIPMF{a} (+1 to the end of epitope KF11) had a decreased replicative capacity. |
Variant ID. | 4659 |
---|---|
Epitope Seq. | {E}KAFSPEVIPMF |
Variant Seq. | {q}KAFSPEVIPMF |
Mutations | E/Q |
Epitope Location | E-1Q |
HXB2 Location | E161Q |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, qKAFSPEVIPMF (-1 to the start of epitope KF11) had at least a 2-fold increase in relative enrichment when cultured with 1 of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity. |
Variant ID. | 4660 |
---|---|
Epitope Seq. | {E}KAFSPEVIPMF |
Variant Seq. | {s}KAFSPEVIPMF |
Mutations | E/S |
Epitope Location | E-1S |
HXB2 Location | E161S |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, sKAFSPEVIPMF (-1 to the start of epitope KF11) had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity. |
Variant ID. | 4661 |
---|---|
Epitope Seq. | {E}KAFSPEVIPMF |
Variant Seq. | {t}KAFSPEVIPMF |
Mutations | E/T |
Epitope Location | E-1T |
HXB2 Location | E161T |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, tKAFSPEVIPMF (-1 to the start of epitope KF11) had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity. |
Variant ID. | 4662 |
---|---|
Epitope Seq. | {E}KAFSPEVIPMF |
Variant Seq. | {a}KAFSPEVIPMF |
Mutations | E/A |
Epitope Location | E-1A |
HXB2 Location | E161A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, aKAFSPEVIPMF (-1 to the start of epitope KF11) had at least a 2-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity. |
Variant ID. | 4663 |
---|---|
Epitope Seq. | KAFSPEVIPMF{S} |
Variant Seq. | KAFaPEVIPMF{t} |
Mutations | S/T S/A |
Epitope Location | S+1T S4A |
HXB2 Location | S173T S165A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFaPEVIPMFt (+1 to the end of epitope KF11) had at least a 5-fold increase in relative enrichment when cultured with 1 of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4664 |
---|---|
Epitope Seq. | KAFSPEVIPMF{S} |
Variant Seq. | KAFSPEVIPMF{g} |
Mutations | S/G |
Epitope Location | S+1G |
HXB2 Location | S173G |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFSPEVIPMFg (+1 to the end of epitope KF11) had a decreased replicative capacity. |
Variant ID. | 4665 |
---|---|
Epitope Seq. | KAFSPEVIPMF{S} |
Variant Seq. | KAFSPEVIPMF{t} |
Mutations | S/T |
Epitope Location | S+1T |
HXB2 Location | S173T |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFSPEVIPMFt (+1 to the end of epitope KF11) had a decreased replicative capacity. |
Variant ID. | 4666 |
---|---|
Epitope Seq. | KAFSPEVIPMF{S} |
Variant Seq. | rAFSPEVIPMF{a} |
Mutations | S/A K/R |
Epitope Location | S+1A K1R |
HXB2 Location | S173A K162R |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, rAFSPEVIPMFa (+1 to the end of epitope KF11) had at least a 2-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity. |
Variant ID. | 4667 |
---|---|
Epitope Seq. | KAFSPEVIPMF{S} |
Variant Seq. | KAFSPEVIPMF{n} |
Mutations | S/N |
Epitope Location | S+1N |
HXB2 Location | S173N |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFSPEVIPMFn (+1 to the end of epitope KF11) had at least a 5-fold increase in relative enrichment when cultured with 1 of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity. |
Variant ID. | 4668 |
---|---|
Epitope Seq. | KAFSPEVIPMF{S} |
Variant Seq. | KnFSPEVIPMF{v} |
Mutations | S/V A/N |
Epitope Location | S+1V A2N |
HXB2 Location | S173V A163N |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KnFSPEVIPMFv (+1 to the end of epitope KF11) had at least a 5-fold increase in relative enrichment when cultured with 1 of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity. |
Variant ID. | 4669 |
---|---|
Epitope Seq. | KAFSPEVIPMF{S} |
Variant Seq. | KAFSPEVIPMF{q} |
Mutations | S/Q |
Epitope Location | S+1Q |
HXB2 Location | S173Q |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFSPEVIPMFq (+1 to the end of epitope KF11) had at least a 2-fold increase in relative enrichment when cultured with 1 of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity. |
Variant ID. | 4670 |
---|---|
Epitope Seq. | KAFSPEVIPMF{S} |
Variant Seq. | KnFSPEVIPMF{t} |
Mutations | S/T A/N |
Epitope Location | S+1T A2N |
HXB2 Location | S173T A163N |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KnFSPEVIPMFt (+1 to the end of epitope KF11) had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity without CTLs. |
Variant ID. | 4671 |
---|---|
Epitope Seq. | KAFSPEVIPMF{S} |
Variant Seq. | KAFSPEVIPMF{v} |
Mutations | S/V |
Epitope Location | S+1V |
HXB2 Location | S173V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFSPEVIPMFv (+1 to the end of epitope KF11) had at least a 2-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity. |
Variant ID. | 4672 |
---|---|
Epitope Seq. | KAFSPEVIPMF{S} |
Variant Seq. | rAFSPEVIPMF{t} |
Mutations | S/T K/R |
Epitope Location | S+1T K1R |
HXB2 Location | S173T K162R |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, rAFSPEVIPMF{t} (+1 to the end of epitope KF11) had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity. |
Variant ID. | 4673 |
---|---|
Epitope Seq. | KAFSPEVIPMF{S} |
Variant Seq. | KAFaPEVIPMF{q} |
Mutations | S/Q S/A |
Epitope Location | S+1Q S4A |
HXB2 Location | S173Q S165A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFaPEVIPMFq (+1 to the end of epitope KF11) had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity. |
Variant ID. | 4674 |
---|---|
Epitope Seq. | KAFSPEVIPMF{S} |
Variant Seq. | rAFSPEVIPMF{q} |
Mutations | S/Q K/R |
Epitope Location | S+1Q K1R |
HXB2 Location | S173Q K162R |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, rAFSPEVIPMF{q} (+1 to the end of epitope KF11) had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity. |
Variant ID. | 4675 |
---|---|
Epitope Seq. | KAFSPEVIPMF{S} |
Variant Seq. | KAFSPEVvPMF{a} |
Mutations | S/A I/V |
Epitope Location | S+1A I8V |
HXB2 Location | S173A I169V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFSPEVvPMFa (+1 to the end of epitope KF11) had at least a 5-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity. |
Variant ID. | 4676 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KAFaPEVIPMF |
Mutations | S/A |
Epitope Location | S4A |
HXB2 Location | S165A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFaPEVIPMF had an increased replicative capacity when cultured without CTLs, but did not have an increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones vs. without CTLs. |
Variant ID. | 4677 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KAFSaEVvPMF |
Mutations | P/A I/V |
Epitope Location | P5A I8V |
HXB2 Location | P166A I169V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFSaEVvPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, suggesting escape mutant potential as defined by the authors. |
Variant ID. | 4678 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KnFSPEVIPMF |
Mutations | A/N |
Epitope Location | A2N |
HXB2 Location | A163N |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KnFSPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, suggesting escape mutant potential as defined by the authors. |
Variant ID. | 4679 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KAFqPEVIPMF |
Mutations | S/Q |
Epitope Location | S4Q |
HXB2 Location | S165Q |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFqPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, suggesting escape mutant potential as defined by the authors. |
Variant ID. | 4680 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KAFSPEiIPMF |
Mutations | V/I |
Epitope Location | V7I |
HXB2 Location | V168I |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFSPEiIPMF had reduced replicative capacity. |
Variant ID. | 4681 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | rAFSPEiIPMF |
Mutations | K/R V/I |
Epitope Location | K1R V7I |
HXB2 Location | K162R V168I |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, rAFSPEiIPMF had at least a 2-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4682 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KAFSPEtIPMF |
Mutations | V/T |
Epitope Location | V7T |
HXB2 Location | V168T |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFSPEtIPMF had at least a 2-fold to 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4683 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KAFSPEVvPMF |
Mutations | I/V |
Epitope Location | I8V |
HXB2 Location | I169V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFSPEVvPMF had at least a 10-fold increase in relative enrichment when cultured with 1 of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4684 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | rAFaPEVIPMF |
Mutations | K/R S/A |
Epitope Location | K1R S4A |
HXB2 Location | K162R S165A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, rAFaPEVIPMF had at least a 2-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4685 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | rAFSPEVIPMF |
Mutations | K/R |
Epitope Location | K1R |
HXB2 Location | K162R |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, rAFSPEVIPMF had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4686 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | rgFSPEVIPMF |
Mutations | K/R A/G |
Epitope Location | K1R A2G |
HXB2 Location | K162R A163G |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, rgFSPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4687 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KAFcPEVIPMF |
Mutations | S/C |
Epitope Location | S4C |
HXB2 Location | S165C |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFcPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4688 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KqFSPEVIPMF |
Mutations | A/Q |
Epitope Location | A2Q |
HXB2 Location | A163Q |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KqFSPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4689 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KAFtPEVIPMF |
Mutations | S/T |
Epitope Location | S4T |
HXB2 Location | S165T |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFtPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4690 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KgFaPEVIPMF |
Mutations | A/G S/A |
Epitope Location | A2G S4A |
HXB2 Location | A163G S165A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KgFaPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4691 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KgFSPEVIPMF |
Mutations | A/G |
Epitope Location | A2G |
HXB2 Location | A163G |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KgFSPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4692 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KAFSaEVIPMF |
Mutations | P/A |
Epitope Location | P5A |
HXB2 Location | P166A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFSaEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4693 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KAFmPEVIPMF |
Mutations | S/M |
Epitope Location | S4M |
HXB2 Location | S165M |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFmPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4694 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KgFqPEVIPMF |
Mutations | A/G S/Q |
Epitope Location | A2G S4Q |
HXB2 Location | A163G S165Q |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KgFqPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4695 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KeFSPEVIPMF |
Mutations | A/E |
Epitope Location | A2E |
HXB2 Location | A163E |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KeFSPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4696 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KsFSPEtIPMF |
Mutations | A/S V/T |
Epitope Location | A2S V7T |
HXB2 Location | A163S V168T |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KsFSPEtIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity. |
Variant ID. | 4697 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KdFSPEVIPMF |
Mutations | A/D |
Epitope Location | A2D |
HXB2 Location | A163D |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KdFSPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity. |
Variant ID. | 4698 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KsFSPEVIPfF |
Mutations | M/F A/S |
Epitope Location | M10F A2S |
HXB2 Location | M171F A163S |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KsFSPEVIPfF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity. |
Variant ID. | 4699 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KgFrPEVIPMF |
Mutations | A/G S/R |
Epitope Location | A2G S4R |
HXB2 Location | A163G S165R |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KgFrPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity. |
Variant ID. | 4700 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KAFSPEcIPMF |
Mutations | V/C |
Epitope Location | V7C |
HXB2 Location | V168C |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFSPEcIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity. |
Variant ID. | 4701 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KAFnPEVIPMF |
Mutations | S/N |
Epitope Location | S4N |
HXB2 Location | S165N |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFnPEVIPMF had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4702 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KsFSPEVIPMF |
Mutations | A/S |
Epitope Location | A2S |
HXB2 Location | A163S |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KsFSPEVIPMF had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, suggesting escape mutant potential as defined by the authors. |
Variant ID. | 4703 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KAFvPEVIPMF |
Mutations | S/V |
Epitope Location | S4V |
HXB2 Location | S165V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFvPEVIPMF had a decreased replicative capacity. |
Variant ID. | 4704 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KAFSPEcvPMF |
Mutations | V/C I/V |
Epitope Location | V7C I8V |
HXB2 Location | V168C I169V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KAFSPEcvPMF had at least a 2-fold to 5-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity. |
Variant ID. | 4705 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KtFSPEVIPMF |
Mutations | A/T |
Epitope Location | A2T |
HXB2 Location | A163T |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KtFSPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with 1 of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Variant ID. | 4706 |
---|---|
Epitope Seq. | KAFSPEVIPMF |
Variant Seq. | KcFSPEVIPMF |
Mutations | A/C |
Epitope Location | A2C |
HXB2 Location | A163C |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, KcFSPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with 1 of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs. |
Gorin2017 Aleksandr M. Gorin, Yushen Du, Franklin Y. Liu, Tian-Hao Zhang, Hwee L. Ng, Christian Hofmann, William G. Cumberland, Ren Sun, and Otto O. Yang. HIV-1 Epitopes Presented by MHC Class I Types Associated with Superior Immune Containment of Viremia Have Highly Constrained Fitness Landscapes. PLoS Pathog, 13(8):e1006541, Aug 2017. PubMed ID: 28787455. Show all entries for this paper.
This is a legacy search page. It is deprecated, will receive no more updates, and will eventually be removed. Please use the new search pages.